PURPOSE: Systemic exposure to mercaptopurine (MP) is critical for durable remissions in children with acute lymphoblastic leukemia (ALL). Nonadherence to oral MP could increase relapse risk and also contribute to inferior outcome in Hispanics. This study identified determinants of adherence and described impact of adherence on relapse, both overall and by ethnicity. PATIENTS AND METHODS: A total of 327 children with ALL (169 Hispanic; 158 non-Hispanic white) participated. Medication event-monitoring system caps recorded date and time of MP bottle openings. Adherence rate, calculated monthly, was defined as ratio of days of MP bottle opening to days when MP was prescribed. RESULTS: After 53,394 person-days of monitoring, adherence declined from 94.7% (month 1) to 90.2% (month 6; P < .001). Mean adherence over 6 months was significantly lower among Hispanics (88.4% v 94.8%; P < .001), patients age ≥ 12 years (85.8% v 93.1%; P < .001), and patients from single-mother households (80.6% v 93.1%; P = .001). A progressive increase in relapse was observed with decreasing adherence (reference: adherence ≥ 95%; 94.9% to 90%: hazard ratio [HR], 4.1; 95% CI,1.2 to 13.5; P = .02; 89.9% to 85%: HR, 4.0; 95% CI, 1.0 to 15.5; P = .04; < 85%: HR. 5.7; 95% CI, 1.9 to 16.8; P = .002). Cumulative incidence of relapse (± standard deviation) was higher among Hispanics (16.5% ± 4.0% v 6.3% ± 2.2%; P = .02). Association between Hispanic ethnicity and relapse (HR, 2.6; 95% CI, 1.1 to 6.1; P = .02) became nonsignificant (HR, 1.8; 95% CI, 0.6 to 5.2; P = .26) after adjusting for adherence and socioeconomic status. At adherence rates ≥ 90%, Hispanics continued to demonstrate higher relapse, whereas at rates < 90%, relapse risk was comparable to that of non-Hispanic whites. CONCLUSION: Lower adherence to oral MP increases relapse risk. Ethnic difference in relapse risk differs by level of adherence-an observation currently under investigation.
PURPOSE: Systemic exposure to mercaptopurine (MP) is critical for durable remissions in children with acute lymphoblastic leukemia (ALL). Nonadherence to oral MP could increase relapse risk and also contribute to inferior outcome in Hispanics. This study identified determinants of adherence and described impact of adherence on relapse, both overall and by ethnicity. PATIENTS AND METHODS: A total of 327 children with ALL (169 Hispanic; 158 non-Hispanic white) participated. Medication event-monitoring system caps recorded date and time of MP bottle openings. Adherence rate, calculated monthly, was defined as ratio of days of MP bottle opening to days when MP was prescribed. RESULTS: After 53,394 person-days of monitoring, adherence declined from 94.7% (month 1) to 90.2% (month 6; P < .001). Mean adherence over 6 months was significantly lower among Hispanics (88.4% v 94.8%; P < .001), patients age ≥ 12 years (85.8% v 93.1%; P < .001), and patients from single-mother households (80.6% v 93.1%; P = .001). A progressive increase in relapse was observed with decreasing adherence (reference: adherence ≥ 95%; 94.9% to 90%: hazard ratio [HR], 4.1; 95% CI,1.2 to 13.5; P = .02; 89.9% to 85%: HR, 4.0; 95% CI, 1.0 to 15.5; P = .04; < 85%: HR. 5.7; 95% CI, 1.9 to 16.8; P = .002). Cumulative incidence of relapse (± standard deviation) was higher among Hispanics (16.5% ± 4.0% v 6.3% ± 2.2%; P = .02). Association between Hispanic ethnicity and relapse (HR, 2.6; 95% CI, 1.1 to 6.1; P = .02) became nonsignificant (HR, 1.8; 95% CI, 0.6 to 5.2; P = .26) after adjusting for adherence and socioeconomic status. At adherence rates ≥ 90%, Hispanics continued to demonstrate higher relapse, whereas at rates < 90%, relapse risk was comparable to that of non-Hispanic whites. CONCLUSION: Lower adherence to oral MP increases relapse risk. Ethnic difference in relapse risk differs by level of adherence-an observation currently under investigation.
Authors: M V Relling; M L Hancock; G K Rivera; J T Sandlund; R C Ribeiro; E Y Krynetski; C H Pui; W E Evans Journal: J Natl Cancer Inst Date: 1999-12-01 Impact factor: 13.506
Authors: B H Pollock; M R DeBaun; B M Camitta; J J Shuster; Y Ravindranath; D J Pullen; V J Land; D H Mahoney; S J Lauer; S B Murphy Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Jun J Yang; Cheng Cheng; Meenakshi Devidas; Xueyuan Cao; Yiping Fan; Dario Campana; Wenjian Yang; Geoff Neale; Nancy J Cox; Paul Scheet; Michael J Borowitz; Naomi J Winick; Paul L Martin; Cheryl L Willman; W Paul Bowman; Bruce M Camitta; Andrew Carroll; Gregory H Reaman; William L Carroll; Mignon Loh; Stephen P Hunger; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Nat Genet Date: 2011-02-06 Impact factor: 38.330
Authors: Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman Journal: Blood Date: 2010-02-04 Impact factor: 22.113
Authors: Smita Bhatia; Harland N Sather; Nyla A Heerema; Michael E Trigg; Paul S Gaynon; Leslie L Robison Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Connie M Trinacty; Alyce S Adams; Stephen B Soumerai; Fang Zhang; James B Meigs; John D Piette; Dennis Ross-Degnan Journal: BMC Health Serv Res Date: 2009-02-07 Impact factor: 2.655
Authors: Kevin A Hommel; Meghan E McGrady; James Peugh; George Zacur; Katherine Loreaux; Shehzad Saeed; Elizabeth Williams; Lee A Denson Journal: Inflamm Bowel Dis Date: 2017-09 Impact factor: 5.325
Authors: Wendy Landier; Yanjun Chen; Lindsey Hageman; Heeyoung Kim; Bruce C Bostrom; Jacqueline N Casillas; David S Dickens; William E Evans; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia Journal: Blood Date: 2017-02-02 Impact factor: 22.113
Authors: Christopher C Denton; Yasmin A Rawlins; Matthew J Oberley; Deepa Bhojwani; Etan Orgel Journal: Pediatr Blood Cancer Date: 2017-12-08 Impact factor: 3.167
Authors: Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala Journal: Biol Blood Marrow Transplant Date: 2016-09-19 Impact factor: 5.742